To elucidate the mechanism of action of aldosterone antagonists, we studied the interaction of spironolactone with the chick mineralocorticosteroid receptor (MR). Intestinal cytosol contains specific spironolactone-binding sites (Kd 3 nM; max. no. of binding sites -100 fmol/mg of protein) that have been identified as MRs by competition experiments with steroid ligands and with the monoclonal anti-idiotypic antibody H1OE that interacts with aldosterone-binding domain of the MR. Binding studies indicate that aldosterone and spironolactone bind to the MR through a common site that encompasses the epitope recognized by H1OE. At 4°C, spironolactone dissociates much more rapidly from the cytosol 8-9 S form of MR (t! 38 min) than does aldosterone (t± 3240 min). A high dissociation rate was also observed for progesterone, a natural aldosterone antagonist (t! 84 min). The covalent linkage of the 90 kDa heat shock protein (hsp90) to the ligand-binding subunit of MR with dimethyl pimelimidate did not notably modify the rate of dissociation of spironolactone from the receptor (t, 96 min), excluding the possibility that the rapid dissociation rate of the antagonist was related to hsp90 release. The effects of aldosterone and the two anti-mineralocorticosteroids on the 8-9 S heterooligomeric structure of the MR differed strikingly. Using low-salt density-gradient centrifugation analysis, aldosteronelabelled receptors were recovered as 8-9S complexes, whereas 4 S entities were detected after spironolactone and progesterone binding. This indicated that, under the experimental conditions used, aldosterone antagonists facilitate hsp90 release and thus do not stabilize the non-DNA-binding 8-9S form of MR. We propose that the combination of rapid dissociation of the ligand and a weakened hsp90-receptor interaction is involved in the anti-mineralococorticosteroid activity of aldosterone antagonists.
INTRODUCTION
Spirolactones, synthetic steroids which are anti-mineralocorticosteroid compounds, act mainly by antagonizing the effect of aldosterone at the target cell level [1] . Spirolactones are widely used as anti-hypertensive agents; however, the molecular basis of their effects remain unclear. It has been proposed that they exert their effects by competitively inhibiting the binding of aldosterone to its intracellular receptor. Marver et al. [2] and Claire et al. [3] reported that tritiated spirolactones bind to the cytosol mineralocorticosteroid receptor (MR). Unlike aldosterone-receptor complexes, spirolactone-labelled receptors were not detected in the nucleus after subcellular fractionation of prelabelled renal tissues. On the basis of these observations, it has been proposed that spirolactone-labelled receptors are unable to be translocated into the nucleus and/or to bind to specific nuclear acceptor sites [2, 3] . However, specific nuclear binding of spironolactone in rabbit kidney cells has recently been detected by autoradiography [4] . It was therefore of interest to determine the steps, in the cascade of events from steroid binding to transcriptional activation, responsible for the antagonist activity of spirolactones.
Steroid receptors are regulatory transcriptional factors that are composed of a steroid-binding unit which is found associated with other cellular components, most notably the 90 kDa heatshock protein (hsp90) [5] [6] [7] . In its hetero-oligomeric structure, the receptor is unable to interact with specific DNA sequences. Activation of the receptor to its DNA-binding state is accompanied by dissociation of hsp9o from the steroid-binding unit [8] . The biological role of the hsp90-receptor association in receptor function is still poorly understood. It has been proposed that hsp90 caps the DNA-binding site of the receptor [8] . Hsp9O has also been shown to protect the receptor against proteolysis, to stabilize the conformation of the functional hormone-binding domain, and thus to be involved in signal transduction [9] [10] [11] [12] .
In a previous study we have shown that the MR of the chick intestine is associated with hsp90 [13] . To gain further insight into the mechanism of action of aldosterone antagonists, we characterized the binding to the chick intestine MR of spironolactone, the only spirolactone which is used for treatment of high blood pressure. We also determined whether the spironolactonebinding site was the same as the one for aldosterone. For this purpose, we took advantage of a monoclonal anti-idiotypic antibody that specifically recognizes the aldosterone-binding site of the MR [14] . In order to detect putative differences between agonist and antagonist in their interaction with the MR, we also examined the binding kinetics of aldosterone, spironolactone and progesterone, a natural aldosterone agonist. Finally, we analysed the effects of agonist and antagonists on the heterooligomeric structure of the MR to determine whether the ligand is a key modulator of the hsp90-receptor interaction, and to determine if the biological activity of a steroid can be correlated with its effects on the oligomeric structure of the receptor. [14] . The rat monoclonal antibody BF4, which reacts with hsp9o, was prepared as described previously [15] .
MATERIALS AND METHODS

Intestinal cytosol preparation
Chickens of the Warren strain (6-8 weeks old) were decapitated, and the intestine was removed, slit longitudinally and washed successively with ice-cold 0.9 % NaCl and TEG or TEGW buffer. The tissue was cut into small pieces and homogenized in TEG or TEGW buffer (2 ml/g) by using an Ultra Turrax tissue homogenizer. The homogenate was centrifuged at 5000 g for 10 min at 4°C, and the resulting supernatant was centrifuged at 105 000 g for 60 min at 4 'C. The final supernatant was frozen in liquid nitrogen until further use.
Covalent cross-linking
The cross-linking conditions used have been described before [16] . To 4 'C, total radioactivity was counted. Bound (B) and unbound (U) steroid were separated by the dextran/charcoal method described previously [13] . The evolution of bound as a function of unbound steroid was analysed by a previously described computer method [17] . Increasingly complex models of interaction were tested, comprising one [13] . Table 1 shows the [3H]- Our data are also in good agreement with those obtained in rat kidney [1, 3] and in toad bladder [19] .
Immunological identification of antagonist-binding site
It is difficult to conclude from the binding competition experiments whether agonist and antagonist bind to the same site or to distinct but interacting sites. Indeed, an allosteric model, in which the antagonist-binding site is different from that of the agonist, has been proposed for steroid receptors [20] [21] [22] . A monoclonal anti-idiotypic antibody (H1OE) which interacts with aldosterone-binding domain of the rabbit MR [14] was an appropriate probe to map the binding site of aldosterone antagonists. As shown in Table 2 , HIOE specifically inhibited aldosterone binding to avian MRs. The cross-reactivity of H1OE for the avian MR is not surprising since HIOE, as an internal image of aldosterone, theoretically should interact with aldosterone-binding sites of the MR regardless of species. As can be observed in Table 2 (mi'n) association between aldosterone and the MR. From our results it is tempting to propose that the anti-mineralocorticosteroid activity of an aldosterone antagonist could be related to its rapid dissociation kinetics. Such a mechanism has already been put forward to account for the anti-glucocorticosteroid activity of several compounds, including 17,f-carboxamide derivatives of dexamethasone [30, 31] . However, RU486 behaves differently, since it dissociates very slowly from the glucocorticosteroid receptor as compared with the agonist [32] . Hsp9O is part of the hetero-oligomeric structure of untransformed receptors. Its association with the receptor has been shown, at least for the glucocorticosteroid receptor [10] , to be necessary to ensure a competent steroid binding site. To confirm that the rapid dissociation of [3H]spironolactone was not secondary to the release of hsp9O, we measured the dissociation rate of spironolactone from the MR in cytosol treated with dimethyl pimelimidate, which induces a covalent bond between hsp90 and the steroid-binding unit [13] . Under these conditions the half-life of the [3H]spironolactone-receptor complex was not notably modified (t, 96 min), and remained far from that of aldosterone (ti 3240 min). form. Such a mechanism has already been proposed for RU486 [33, 34] and other non-steroidal anti-glucocorticosteroids [35] . To answer this question we examined the MR structure upon agonist and antagonist binding.
In a previous paper [13] we reported that, in sodium tungstatecontaining buffer, the aldosterone-receptor complex was recovered associated with hsp90. A hetero-oligomeric structure of MR could be also observed under the same conditions when the receptor was labelled with spironolactone. This was evidenced by a 8.9S-+ 10.4S shift of the spironolactone-receptor complex induced by BF4, a monoclonal anti-hsp9o antibody (Fig. 3) . The effect of ligand on hsp90-receptor interaction was further examined using glycerol gradients under free oxyanion conditions. When the cytosol and the glycerol gradient buffers were prepared in the absence of sodium tungstate, aldosterone-labelled receptors sedimented in the 8-9S region (Fig. 4a) . In contrast, both [3H]spironolactone-and [3H]progesterone-receptor complexes sedimented as specific 4S peaks (Figs. 4b and 4c ). The release of hsp90 from the antagonist-bound MR was timedependent, since it was observed after 18 h (centrifugation in a SW60 rotor) but not after 3 h (centrifugation in a VTi 80 rotor) (results not shown). This hsp9o release is inhibited by oxyanions (compare Figs. 3 and 4b) . Our results indicate that, in contrast to aldosterone, spironolactone and progesterone are unable to maintain the hetero-oligomeric structure even under low-salt conditions. They also strongly support a major role of the ligand in modulating the interaction between hsp90 and MR, and suggest that the steroid-binding domain of the MR is implicated in the interaction with hsp90. This is in good agreement with studies on the glucocorticosteroid receptor [36] [37] [38] [39] , the progesterone receptor [40] and the oestrogen receptor [41] , which have reported that the ligand-binding domain of the receptor is involved in the interaction with hsp90.
The aim of the present study was to gain a better understanding of the molecular basis of the anti-mineralocorticosteroid actions
